S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine

Journal of Pharmacology and Experimental Therapeutics

Volumn 298, Issue 2, 2001, Pages 565-580

  Millan, Mark J ^a   Gobert, Alain ^a   Lejeune, Françoise ^a   Newman Tancredi, Adrian ^a   Rivet, Jean Michel ^a   Auclair, Agnès ^a   Peglion, Jean Louis ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORAMPHETAMINE; CITALOPRAM; CLOMIPRAMINE; IDAZOXAN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; NORADRENALIN TRANSPORTER; REBOXETINE; S 33005; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VENLAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BRAIN REGION; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DORSAL RAPHE NUCLEUS; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; MALE; NERVE POTENTIAL; NONHUMAN; NORADRENALIN BRAIN LEVEL; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SEROTONIN BRAIN LEVEL; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM;

ANIMALS; BRAIN CHEMISTRY; CARRIER PROTEINS; CITALOPRAM; CLOMIPRAMINE; CYCLOHEXANOLS; ELECTROPHYSIOLOGY; HUMANS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MORPHOLINES; NERVE TISSUE PROTEINS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; P-CHLOROAMPHETAMINE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SYMPORTERS;

EID: 0034918693     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders
2. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode
3. Norepinephrine dysfunction in depression
4. Norepinephrine and serotonin transporters: Molecular targets for antidepressant drugs
5. Vanlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites
6. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: 1. In vivo electrophysiological studies in the rat
7. Biogenic amine transporters: Regulation in flux
8. Current advances and trends in the treatment of depression
9. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
10. Prospects for improved antidepressants
11. Short-term treatment of mood disorders with standard antidepressants
12. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: A review
13. 1A receptor antagonism
14. 1d-adrenergic receptor mRNA in the rat brain and spinal cord
15. Venlafaxine: Measuring the onset and antidepressant action
16. Blunting of reactivity of dopamine transmission of palatable food: A biochemical marker of anhedonia in the CMS model?
17. Treatment of major depression: Is improvement enough?
18. Antidepressants
19. Fluexetine, a selective inhibitor of serotonin uptake
20. 1A autorecopters and noradrenergic mechanisms
21. Selective serotonin reuptake inhibitors in affective disorders: I. Basic pharmacology
22. Noradrenergic denervation prevents sensitization of rat forebrain neurons to serotonin by tricyclic antidepressant treatment
23. Noradrenergic modulation of central serotonergic neurotransmission: Acute and long-term actions of mirtazapine
24. Evidence of the dual mechanisms of action of venlafaxine
25. Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs
26. 2-adrenoceptors in the prefrontal cortex
27. 3H]GBR-12935 binding in brain: A radioligand for selective labelling of the dopamine transport complex
28. The question of feedback at the somadendritic region and antidepressant drug action
29. Dominant negative isoform of rat norepinephrine transporter produced by alternative RNA splicing
30. The serotonin hypothesis of major depression
31. Prefrontal cortical dysfunction in depression determined by Wisconsin card sorting test performance
32. 18F]setoperone PET imaging study
33. 2C receptors: A comparison with citalopram
34. Reciprocal autoreceptor and heteroceptor control of serotonergic, dopaminergic and adrenergic transmission in frontal cortex: A review, and relevance to the actions of antidepressant agents
35. 2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity
36. 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration
37. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative
38. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine
39. Lack of β adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine
40. 3H]CGP-12177 binding reveals rapid (24 hour) modulation
41. Is the β-AR down-regulation a prerequisite of the antidepressant activity?
42. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
43. 2C receptor
44. Venlafaxine and paroxetine in treatment-resistant depression
45. Preclinical pharmacology of citalopram
46. Fluexetine increases extracellular dopamine in the prefrontal cortex by mechanism not dependent on serotonin: A comparison with citalopram
47. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area
48. Role of norepinephrine in the pathophysiology and treatment of mood disorders
49. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
50. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: Behavioural and biochemical studies
51. Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain
52. Development of new antidepressants
53. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression
54. Vanlafaxine, a novel antidepressant compound
55. Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat
56. Distinct effects of imipramine on 5-hydroxytryptamine uptake mediated by the recombinant rat serotonin transporter SERT1
57. Pharmacological profile of antidepressants and related compounds at human monoamine transporters
58. Dopaminergic mechanisms in depression and mania
59. Reboxetine a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor
60. Regulation of extracellular dopamine by the norepinephrine transporter
61. 2 receptor binding in patients with major depression following desipramine treatment
62. 2 receptors in major depression. A positron emission tomography study
63. Stressor-induced anhedonia in the mesocorticolimbic system